When Oncologie launched last year, it highlighted its trendy model of operating between Boston and Shanghai amid a wave of Chinese capital eager to back experienced US execs in developing Western cancer drugs for the Asian market. For its Series B, it’s allying itself with another buzzy concept in the industry — choosing the right patients by biomarkers.